Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751537 · ClinicalTrials.gov registry record
Effectiveness of the WearME System for COPD Severity and Respiratory Function
A clinical trial of Chronic Obstructive Pulmonary Disease (COPD), sponsored by LASARRUS Clinic and Research Center.
- Recruiting
- Registry status
- 128
- Enrollment target
- 2
- Study locations
NCT06751537: Recruiting study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by LASARRUS Clinic and Research Center.
NCT06751537 is a study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by LASARRUS Clinic and Research Center. The registered enrollment target is 128 participants, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06751537, a study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by LASARRUS Clinic and Research Center.
- RECRUITING
- Registry status
- 128 participants
- Enrollment target
- 2
- Study locations
Study Summary
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in 128 COPD participants.
Primary Outcome
The primary outcome measure will be the Bland-Altman LOA between the FEV1/FVC measurements of WearME-Pro FEV1/FVC prediction (recorded within the WearME-Basic app but not displayed to users) and the gold standard devices.
Conditions Studied
Study Locations (2)
Maryland
- Johns Hopkins - Baltimore
- TidalHealth - Salisbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2026-02-28 |
What NCT06751537 shows while recruiting
NCT06751537 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 0 interventions.
NCT06751537 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06751537 about?
NCT06751537 is a clinical study titled "Effectiveness of the WearME System for COPD Severity and Respiratory Function". This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in 128 COPD participants.
What is the current status of trial NCT06751537?
This trial is currently recruiting. The enrollment target is 128 participants. The study started on 2025-05-29. Estimated completion is 2026-02-28.
What conditions does trial NCT06751537 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
Who is sponsoring clinical trial NCT06751537?
This trial is sponsored by LASARRUS Clinic and Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751537 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06751537's enrollment target sits among peer trials
128 26th of 36 higher than 11 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI